Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00989417
Other study ID # FRA041
Secondary ID
Status Completed
Phase N/A
First received October 2, 2009
Last updated May 24, 2011
Start date January 2007
Est. completion date October 2010

Study information

Verified date May 2011
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: Direction Générale de la SantéFrance: French Data Protection AuthorityFrance: Institutional Ethical CommitteeFrance: Ministry of Health
Study type Interventional

Clinical Trial Summary

In many aspects of every-day life, modern communication systems bring about a remarkable increase in comfort and safety by transmitting data and information in an easy and reliable manner. In order to provide these advantages also to patients with implantable cardioverter-defibrillators, as well as to their physicians, BIOTRONIK has developed a long-distance implant telemetry to enable periodic trend and event-triggered transmissions of implant data and intracardiac electrogram over distances of several meters. The data is received by a patient device and subsequently automatically transferred to a BIOTRONIK Service Center that provides it to the physician on a password secured internet site. Hence, the physician receives diagnostic information without the patient having to visit the physician (Home Monitoring, HM). New possibilities will arise for a detailed medical and event-correlated supervision of the patient's therapy using electrically active implants.


Description:

State-of-the-art implantable cardioverter defibrillators (ICD) provide a variety of algorithms to optimize episode classification and to minimize the danger of delivering inadequate therapies. An important role in checking the correctness of episode detection, classification and treatment plays the intracardiac electrogram (IEGM), which is stored inside the ICD for every detected episode. However, to analyze the stored IEGM, the physician has to interrogate the implant, i.e. the patient has to visit the ICD ambulance for follow-up. As a result, follow-ups are performed principally to corroborate that the ICD has correctly classified and treated detected tachycardia episodes, to optimize the parameters and in case of adverse event detection, to modify the programmation.

The extension of BIOTRONIK Home MonitoringĀ® by IEGM-OnlineĀ® with LUMOS ICD offers a new possibility to meet the following challenge:

Due to its integrated long-distance telemetry, the implantable cardioverter defibrillator (ICD) LUMOS is capable of periodically transmitting data and IEGM-online from the ICD memory to the BIOTRONIK Service Center via patient device. The BIOTRONIK Service Center decodes the data and presents it to the physician on a password secured internet site. Additionally, in case certain event criteria are met, the most important Home Monitoring information is immediately faxed to the physician as an Event Report. These events can be customized by the physician. Thus, the physician will be able to closely monitor the patient and check the adequacy and efficiency of the ICD therapy without requiring the patient to visit the physician. The transmitted data comprise information on atrial and ventricular rhythm, atrioventricular conduction and system status.

The purpose of the present study is to evaluate the safety and economic impact of ICD follow-up schedule with Home Monitoring in France. For this assessment, the investigation compares two groups: For the ACTIVE group, after a first follow-up, the patients are only followed by Home Monitoring and one follow-up per year. The ICD follow-up or therapeutic intervention will be primarily based and triggered on event reports reception and after cardio reports and IEGM-online analysis on internet site. The findings from this group will be compared to those of a group receiving standard of care (CONTROL group). Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed. The clinical study will analyse, the incidence of significant serious adverse events (composite of all-cause mortality, cardiac and device related SAE), the costs reduction, the home-monitoring workload, the quality of life, the incremental Costs/Effectiveness ratio, the patient willing-to-pay, the delay of Home Monitoring to manage adverse events, the sensitivity of Home Monitoring to detect ICD dysfunctions, the inappropriate therapies rate and impact on hospitalization, the number of ICD charge and impact on battery longevity.

The trial will be conducted as a prospective, randomized, open, multicenter, national clinical trial. The enrolment of 400 patients in 40 clinical centres in France is anticipated


Recruitment information / eligibility

Status Completed
Enrollment 473
Est. completion date October 2010
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Indication for single or dual chamber ICD

Exclusion Criteria:

- NYHA class IV

- Pregnant woman or woman who plan to become pregnant during the trial

- Patient whose medical situation is not stable

- Presence of any disease, other than patient's cardiac disease, associated with reduced likelihood of survival for the duration of the trial, e.g. cancer, uraemia (urea > 70mg/dl or creatinine >3mg/dl), liver failure, etc.

- Age < 18 years

- Patient unable to handle Home Monitoring system correctly

- The patient is not willing and able to comply with the protocol

- Change of residence expected during study

- Insufficient GSM coverage at patient's home

- Participation in another clinical study

- Patient unwilling to sign the consent for participation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Other:
ACTIVATION of HOME MONITORING
Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.

Locations

Country Name City State
France CHRU de Lille- Hôpital Cardiologique Lille

Sponsors (1)

Lead Sponsor Collaborator
Biotronik SE & Co. KG

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with more than one Significant Serious Adverse Event (SSAE) since home-monitoring activation. SSAE is a composite comprising all-cause mortality, cardiac or device related Serious Adverse Events 27 months Yes
Secondary Total costs minimization analyse 27 months No
Secondary Delay of Home Monitoring to manage adverse events 27 months Yes
Secondary Sensitivity of Home Monitoring to detect ICD dysfunction 27 months Yes
Secondary Number of capacitor charge and incidence on ICD-battery longevity 27 months No
Secondary Difference of cardiac and device related Adverse Event 27 Months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Active, not recruiting NCT03700125 - Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 ) N/A
Not yet recruiting NCT05325385 - Ventricular Fibrillation Following Out-of-hospital Cardiac Arrest
Completed NCT00139542 - AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Phase 3
Completed NCT00241800 - Medications and the Risk of Sudden Cardiac Death N/A
Completed NCT00119847 - Electrophysiological Effects of Late PCI After MI N/A
Completed NCT00004560 - Public Access Defibrillation (PAD) Community Trial Phase 3
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000502 - Evaluation of SC-V Versus Conventional CPR Phase 3
Completed NCT00000492 - Beta-Blocker Heart Attack Trial (BHAT) Phase 3
Completed NCT04080986 - DOuble SEquential External Defibrillation for Refractory VF N/A
Completed NCT01789554 - The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01089634 - Left Ventricular Capture Management Study
Completed NCT00382928 - Automatic External Defibrillation Monitoring in Cardiac Arrest Phase 1
Completed NCT01161589 - First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data N/A
Terminated NCT00776087 - European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) N/A
Recruiting NCT04576130 - A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation N/A